文献速递遗传性与小管间质肾病

小分子PAK4抑制剂KPT-9274的抗囊生成活性可能成为常染色体显性多囊肾病的新疗法

Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
PubMed 文献 · Kidney Int · 2017-05-23

常染色体显性多囊肾病(ADPKD)缺乏靶向治疗。基于β-catenin信号与肾纤毛病的关联及ADPKD与癌症的相似性,评估口服小分子KPT-9274(PAK4与烟酰胺磷酸核糖转移酶双重抑制剂)治疗ADPKD。该化合物可降低PAK4蛋白水平、调控β-catenin信号、抑制细胞增殖并诱导凋亡,在体外和早期小鼠模型中抑制囊生成,且未显示毒性,提示可作为ADPKD的潜在疗法进行临床试验。

要点

  • KPT-9274可降低PAK4蛋白水平并调控β-catenin信号。
  • KPT-9274抑制PKD细胞增殖并诱导凋亡,对正常细胞影响较小。
  • KPT-9274在体外和早期小鼠模型中抑制囊生成且未显示毒性。

核心结论

  • KPT-9274可能作为ADPKD的可行疗法进入临床试验评估。

研究设计与样本

  • 研究使用PKD来源细胞、Pkd1-null小鼠细胞系、环磷酸腺苷诱导的体外囊生成模型及早期Pkd1flox/flox:Pkhd1-Cre小鼠模型评估KPT-9274。

主要发现

  • KPT-9274降低PAK4稳态蛋白水平并调控β-catenin信号,同时抑制烟酰胺磷酸核糖转移酶。
  • KPT-9274减弱多种Pkd1-null小鼠细胞系的细胞增殖并诱导凋亡,伴随活性(磷酸化)PAK4和β-catenin减少,对表型正常细胞效果较弱。
  • KPT-9274在体外环磷酸腺苷诱导的囊生成模型及早期Pkd1flox/flox:Pkhd1-Cre小鼠模型中抑制囊生成,后者证实了特异性抗增殖、促凋亡和靶向效应。
  • KPT-9274对NAD生物合成的减弱在高度增殖的癌细胞中关键,但在囊生成过程中生长较慢的囊性上皮细胞中似乎不重要。
  • KPT-9274在ADPKD动物模型或其他癌症模型中未显示毒性。

临床怎么用

  • KPT-9274作为口服小分子PAK4抑制剂,可能为ADPKD提供靶向治疗选择,但需进一步临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common hereditary renal disease with no currently available targeted therapies. Based on the established connection between β-catenin signaling and renal ciliopathies, and on data from our and other laboratories showing striking similarities of this disease and cancer, we evaluated the use of an orally bioavailable small molecule, KPT-9274 (a dual inhibitor of the protein kinase PAK4 and nicotinamide phosphoribosyl transferase), for treatment of ADPKD. Treatment of PKD-derived cells with this compound not only reduces PAK4 steady-state protein levels and regulates β-catenin signaling, but also inhibits nicotinamide phosphoribosyl transferase, the rate-limiting enzyme in a key NAD salvage pathway. KPT-9274 can attenuate cellular proliferation and induce apoptosis associated with a decrease in active (phosphorylated) PAK4 and β-catenin in several Pkd1-null murine cell lines, with a less pronounced effect on the corresponding phenotypically normal cells. Additionally, KPT-9274 shows inhibition of cystogenesis in an ex vivo model of cyclic AMP-induced cystogenesis as well as in the early stage Pkd1flox/flox:Pkhd1-Cre mouse model, the latter showing confirmation of specific anti-proliferative, apoptotic, and on-target effects. NAD biosynthetic attenuation by KPT-9274, while critical for highly proliferative cancer cells, does not appear to be important in the slower growing cystic epithelial cells during cystogenesis. KPT-9274 was not toxic in our ADPKD animal model or in other cancer models. Thus, this small molecule inhibitor could be evaluated in a clinical trial as a viable therapy of ADPKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Hwang VJ, Zhou X, Chen X, et al. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease. Kidney Int. 2017. PMID: 28545714. doi:10.1016/j.kint.2017.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。